

# QuickCheck™ | Rare Blood Disorders

Phone: 1-844-668-6732  
Fax: 1-866-488-6576

Monday - Friday  
8:00 AM to 8:00 PM ET



**NovoCare**<sup>®</sup>  
Savings | Coverage | Support

\* Indicates a required field

PATIENT/INSURANCE INFORMATION	<b>Patient name:</b> *			DOB (MM/DD/YYYY):*		
	Gender <sup>†</sup> :* <input type="checkbox"/> Male <input type="checkbox"/> Female		Preferred language: <input type="checkbox"/> English <input type="checkbox"/> Spanish <input type="checkbox"/> Other:			
	Home address (No P.O. box):			City:	State:	Zip:*
	Shipping address (If different from Home Address):			City:	State:	Zip:*
	Email:		Primary phone:		Ship drug to: <input type="checkbox"/> Patient's home <input type="checkbox"/> Prescribing HCP	
	Primary guardian/caregiver (required if patient under 18 years old):*				Relationship to patient:	
	<b>Primary pharmacy insurance:</b> (Please attach a copy of the insurance card if available)					Phone:
	Rx # ID:	Rx Group #:	Rx PCN #:	Rx BIN #:		
	<b>Secondary pharmacy insurance:</b> (Please attach a copy of the insurance card if available)					Phone:
	Rx # ID:	Rx Group #:	Rx PCN #:	Rx BIN #:		
<b>Employer name:</b>			Employer group #:			
<sup>†</sup> Novo Nordisk and its partners recognize that patients may not identify as male or female. However, many insurance companies still require that one of these two fields be used for each of their members. Please indicate the gender on file with the patient's insurance company.						
DIAGNOSIS	<b>What is the primary diagnosis for which you are prescribing a Novo Nordisk factor product? (required)*</b>					
	<input type="checkbox"/> D66 - Congenital hemophilia A (without inhibitors)		<input type="checkbox"/> D68.2 - Other congenital factor deficiency (FXIII)			
	<input type="checkbox"/> D66 - Congenital hemophilia A (with inhibitors)		<input type="checkbox"/> D68.311 - Acquired hemophilia			
	<input type="checkbox"/> D67 - Congenital hemophilia B (without inhibitors)		<input type="checkbox"/> D69.1 - Qualitative platelet defect (Glanzmann's Thrombasthenia)			
	<input type="checkbox"/> D67 - Congenital hemophilia B (with inhibitors)		<b>Other diagnosis:</b>			
<input type="checkbox"/> D68.2 - Other congenital factor deficiency (FVII)		ICD-10 code and description: _____				
PRODUCT	<b>Select Product:</b>					
	<input type="checkbox"/> NovoSeven <sup>®</sup> RT		<input type="checkbox"/> Novoeight <sup>®</sup>		<input type="checkbox"/> Tretten <sup>®</sup>	
	<input type="checkbox"/> 1 mg <input type="checkbox"/> 2 mg <input type="checkbox"/> 5 mg <input type="checkbox"/> 8 mg		<input type="checkbox"/> 250 IU <input type="checkbox"/> 500 IU <input type="checkbox"/> 1000 IU <input type="checkbox"/> 1500 IU <input type="checkbox"/> 2000 IU <input type="checkbox"/> 3000 IU		<input type="checkbox"/> 2500 IU	
	<input type="checkbox"/> Rebiny <sup>®</sup>		<input type="checkbox"/> Esperoct <sup>®</sup>			
	<input type="checkbox"/> 500 IU <input type="checkbox"/> 1000 IU <input type="checkbox"/> 2000 IU <input type="checkbox"/> 3000 IU		<input type="checkbox"/> 500 IU <input type="checkbox"/> 1000 IU <input type="checkbox"/> 1500 IU <input type="checkbox"/> 2000 IU <input type="checkbox"/> 3000 IU			
Product name:		Dose:	Directions:		Qty:	
Do you intend to buy and bill? <input type="checkbox"/> Yes <input type="checkbox"/> No						
PRESCRIBER AUTHORIZATION	Prescriber name:*			Preferred method of contact: <input type="checkbox"/> Phone <input type="checkbox"/> Fax <input type="checkbox"/> Email		
	Practice name and office contact:				Tax ID #:	
	NPI #:*		Phone:*	Fax:*	Email:*	
	Address:*			City:*	State:*	Zip:*
	<b>Prescriber release:</b> * By signing below, I hereby certify that: (a) I am a licensed practitioner, in good standing under applicable state law; (b) in my medical judgment, I have determined that the product being prescribed is to treat a diagnosis(es) consistent with indications, dosing, and appropriate uses as described in the product's prescribing information; (c) the information I have provided on this enrollment form is, to the best of my knowledge, true, complete, and accurate in all respects; and (d) I have obtained the necessary authorization from the patient, or where appropriate the patient's parent, caregiver, and/or legal representative to use, disclose, share, and/or release the above-referenced information along with other protected health information (as defined in the Health Insurance Portability and Accountability Act of 1996 ("HIPAA")) for the sole purpose of providing patient assistance. Further, I appoint NovoCare <sup>®</sup> , on my behalf, to convey this prescription to the dispensing pharmacy. I will immediately notify Novo Nordisk Inc, its employees, or partners, including AssistRx, Inc. (collectively, "NovoCare <sup>®</sup> ") if the above-named patient, or where appropriate the patient's parent, caregiver, and/or legal representative, revokes their consent to share their PHI with NovoCare <sup>®</sup> . I give you permission to contact me with any questions related to NovoCare <sup>®</sup> .					
	<b>Prescriber signature</b> (no signature stamps):*					Date:*